CA3098293A1 - Slc26a3 inhibitors and use thereof - Google Patents

Slc26a3 inhibitors and use thereof Download PDF

Info

Publication number
CA3098293A1
CA3098293A1 CA3098293A CA3098293A CA3098293A1 CA 3098293 A1 CA3098293 A1 CA 3098293A1 CA 3098293 A CA3098293 A CA 3098293A CA 3098293 A CA3098293 A CA 3098293A CA 3098293 A1 CA3098293 A1 CA 3098293A1
Authority
CA
Canada
Prior art keywords
optionally substituted
pharmaceutical composition
compound
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3098293A
Other languages
English (en)
French (fr)
Inventor
Alan S. Verkman
Onur CIL
Peter M. HAGGIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3098293A1 publication Critical patent/CA3098293A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA3098293A 2018-04-25 2019-04-25 Slc26a3 inhibitors and use thereof Pending CA3098293A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662574P 2018-04-25 2018-04-25
US62/662,574 2018-04-25
PCT/US2019/029219 WO2019210103A2 (en) 2018-04-25 2019-04-25 Slc26a3 inhibitors and use thereof

Publications (1)

Publication Number Publication Date
CA3098293A1 true CA3098293A1 (en) 2019-10-31

Family

ID=67439317

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3098293A Pending CA3098293A1 (en) 2018-04-25 2019-04-25 Slc26a3 inhibitors and use thereof

Country Status (6)

Country Link
US (2) US11591304B2 (https=)
EP (1) EP3784229A2 (https=)
JP (1) JP7442824B2 (https=)
AU (1) AU2019257722B2 (https=)
CA (1) CA3098293A1 (https=)
WO (1) WO2019210103A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019005196A1 (de) * 2019-07-25 2021-01-28 Forschungszentrum Jülich GmbH Verfahren zur Herstellung eines Cumarin-caged Forskolinderivats, Forskolinderivat und Verwendung des Forskolinderivats
WO2023009836A1 (en) 2021-07-30 2023-02-02 The Regents Of The University Of California Slc26a3 inhibitors and use thereof
WO2023081967A1 (en) * 2021-11-10 2023-05-19 The University Of Western Australia Compounds and uses therefor
CN117298113A (zh) * 2023-10-31 2023-12-29 东南大学 替那帕诺及其脂质体靶向m2巨噬细胞在抗肿瘤药中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101362722B (zh) * 2008-09-27 2011-04-27 山东大学 N-取代苯基-2-(1-芳基-1h-咪唑-2-巯基)乙酰胺类衍生物及其制备方法与应用
WO2010056914A1 (en) * 2008-11-12 2010-05-20 Microbiotix, Inc. Bacterial helicase inhibitor compounds and uses thereof
EP3419612B1 (en) 2016-02-26 2024-11-06 The Regents of the University of California Heterocyclic small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions

Also Published As

Publication number Publication date
US11591304B2 (en) 2023-02-28
WO2019210103A3 (en) 2020-01-16
AU2019257722B2 (en) 2025-04-03
WO2019210103A2 (en) 2019-10-31
AU2019257722A1 (en) 2020-11-19
US20230339878A1 (en) 2023-10-26
JP2021522255A (ja) 2021-08-30
EP3784229A2 (en) 2021-03-03
US20210363123A1 (en) 2021-11-25
US12187694B2 (en) 2025-01-07
JP7442824B2 (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
US12187694B2 (en) SLC26A3 inhibitors and use thereof
ES2578735T3 (es) Isotiazolopiridinonas útiles para el tratamiento de (entre otros) fibrosis quística
CA2793856C (en) Tetrahydrobenzothiophene compound
JP2009521468A (ja) Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
TR201806882T4 (tr) Selektif östrojen reseptörü yıkıcıları olarak benzotiofen türevleri ve bunların bileşimleri.
KR20140105445A (ko) 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
WO2008062740A1 (fr) Composé azoté à anneaux fusionnés et son utilisation
TW200402291A (en) Antiallergic
KR20170082494A (ko) 결정 형태의 글루타미나아제 억제제
CN102766103B (zh) 2-硫代-4-胺基-1-萘酚衍生物、其制备方法和用途
CA2379657A1 (en) Phosphate transport inhibitors
CN105873913A (zh) 靶向截短的腺瘤性结肠息肉(apc)蛋白的治疗法
CA2408667A1 (en) Phosphate transport inhibitors
EP3317255A1 (en) Aryl sulfonamide compounds as carbonic anhydrase inhibitors and their therapeutic use
CN111943906A (zh) 脒类衍生物、及其制法和药物组合物与用途
EP4071140B1 (en) Cftr regulators and methods of use thereof
CN112912078B (zh) 用于治疗雌激素受体阳性乳腺癌的组合疗法
JP2002322058A (ja) ミトコンドリア機能賦活剤
WO2020199945A1 (zh) 一类邻位羰基氨基取代苯衍生物、其制备方法和用途
HK1139666B (en) Modulators of cystic fibrosis transmembrane conductance regulator

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240422

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250418

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250418

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250429

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250516

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250916